【レポートの概要(一部)】
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 26
2.1 Catalyst 26
2.2 Related Reports 27
2.3 Upcoming Related Reports 27
3 Disease Overview 28
3.1 Etiology and Pathophysiology 28
3.1.1 Etiology 28
3.1.2 Pathophysiology 29
3.1.3 Basic Breast Anatomy 30
3.2 Disease Classification/Staging Systems 31
3.3 Symptoms 33
3.4 Prognosis 33
3.5 Quality of Life 34
4 Epidemiology 37
4.1 Disease Background 37
4.2 Risk Factors and Comorbidities 37
4.2.1 A family history of breast cancer and BRCA1/2 gene mutations significantly increase the breast cancer risk 39
4.2.2 Reproductive hormonal factors influence the risk of breast cancer 39
4.2.3 Modifiable lifestyle-related factors increase the risk of mortality in breast cancer patients 41
4.2.4 Screening programs have been shown to reduce breast cancer mortality, although the benefits need to be carefully weighed against the risks 43
4.3 Global Trends 46
4.3.1 Incidence 46
4.3.2 Prevalence and Survival 52
4.4 Forecast Methodology 56
4.4.1 Sources Used 58
4.4.2 Sources Not Used 62
4.4.3 Forecast Assumptions and Methods 63
4.5 Epidemiological Forecast for Breast Cancer (2013-2023) – Diagnosed Incident Cases 66
4.5.1 Diagnosed Incident Cases of Breast Cancer 66
4.5.2 Diagnosed Incident Cases of Breast Cancer by Age 68
4.5.3 Diagnosed Incident Cases of Breast Cancer by Menopausal Status 70
4.5.4 Diagnosed Incident Cases of Breast Cancer Segmented by Stage at Diagnosis 72
4.5.5 Age-Standardized Diagnosed Incidence Rate of Breast Cancer 73
4.6 Epidemiological Forecast for Breast Cancer (2013-2023) — Diagnosed Prevalent Cases 74
4.6.1 Five-Year Diagnosed Prevalent Cases of Breast Cancer 74
4.6.2 Five-Year Diagnosed Prevalent Cases by Menopausal Status 76
4.6.3 Five-Year Diagnosed Prevalent Cases by Hormone Receptor Subtypes 77
4.7 Discussion 79
4.7.1 Epidemiological Forecast Insight 79
4.7.2 Limitations of the Analysis 81
4.7.3 Strengths of the Analysis 82
5 Disease Management 84
5.1 Diagnosis and Treatment Overview 84
5.1.1 Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB) 84
5.1.2 Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIC) 86
5.1.3 Treatment Guidelines and Leading Prescribed Drugs 90
5.2 US 91
5.2.1 Diagnosis 91
5.2.2 Clinical Practice 92
5.3 France 95
5.3.1 Diagnosis 95
5.3.2 Clinical Practice 96
5.4 Germany 99
5.4.1 Diagnosis 99
5.4.2 Clinical Practice 100
5.5 Italy 103
5.5.1 Diagnosis 103
5.5.2 Clinical Practice 104
5.6 Spain 106
5.6.1 Diagnosis 106
5.6.2 Clinical Practice 107
5.7 UK 110
5.7.1 Diagnosis 110
5.7.2 Clinical Practice 111
5.8 Japan 114
5.8.1 Diagnosis 114
5.8.2 Clinical Practice 115
5.9 China 117
5.9.1 Diagnosis 117
5.9.2 Clinical Practice 119
6 Competitive Assessment 122
6.1 Overview 122
6.2 Product Profiles (Branded Therapies) 123
6.2.1 Abraxane (nab-paclitaxel) 123
6.2.2 Afinitor (everolimus) 128
6.2.3 Avastin (bevacizumab) 133
6.2.4 Doxil/Caelyx (pegylated liposomal doxorubicin) 137
6.2.5 Halaven (eribulin mesylate) 142
6.2.6 Ixempra (ixabepilone) 145
6.2.7 Xeloda (capecitabine) 148
6.3 Product Profiles (Hormonal Agents) 151
6.3.1 Tamoxifen 151
6.3.2 Faslodex (fulvestrant) 151
6.3.3 Aromatase Inhibitors 152
7 Unmet Need and Opportunity 156
7.1 Overview 156
7.1.1 Defined treatment plan for BRCA mutation-positive patients and prevention of prophylactic surgeries 158
7.1.2 Specific treatment options for TNBC patients 160
7.1.3 Prevention of brain metastasis 161
7.1.4 Neoadjuvant therapy that can downstage tumors 163
7.1.5 For HR+patients, reduced resistance to hormonal agents 164
7.1.6 Improved convenience of administration of hormonal agents 166
8 Pipeline Assessment 168
8.1 Overview 168
8.1.1 Abemaciclib (LY2835219) 169
8.1.2 Buparlisib (BKM- 120) 175
8.1.3 Javlor (vinflunine) 181
8.1.4 LEE011 185
8.1.5 NeuVax (nelipepimut-S/E75) 190
8.1.6 Niraparib (MK4827) 195
8.1.7 NKTR- 102 (etirinotecan pegol) 200
8.1.8 Lynparza (olaparib) 204
8.1.9 Palbociclib (PD-0332991) 209
8.1.10 Talazoparib (BMN 673) 215
8.1.11 Veliparib (ABT-888) 219
8.2 Promising Drugs in Clinical Development 224
8.2.1 PD-/PD-L 1 Immunotherapies 225
9 Current and Future Players 227
9.1 Overview 227
9.2 Trends in Corporate Strategy 229
9.3 Company Profiles 232
9.3.1 AstraZeneca 232
9.3.2 Bristol-Myers Squibb 233
9.3.3 Eli Lilly 235
9.3.4 Pfizer 236
9.3.5 Novartis/GlaxoSmithKline 239
10 Market Outlook 241
10.1 Global Markets 241
10.1.1 Forecast 241
10.1.2 Drivers and Barriers – Global Issues 247
10.2 US 249
10.2.1 Forecast 249
10.2.2 Key Events 252
10.2.3 Drivers and Barriers 253
10.3 France 255
10.3.1 Forecast 255
10.3.2 Key Events 258
10.3.3 Drivers and Barriers 259
10.4 Germany 260
10.4.1 Forecast 260
10.4.2 Key Events 264
10.4.3 Drivers and Barriers 265
10.5 Italy 266
10.5.1 Forecast 266
10.5.2 Key Events 270
10.5.3 Drivers and Barriers 271
10.6 Spain 272
10.6.1 Forecast 272
10.6.2 Key Events 275
10.6.3 Drivers and Barriers 276
10.7 UK 277
10.7.1 Forecast 277
10.7.2 Key Events 281
10.7.3 Drivers and Barriers 282
10.8 Japan 284
10.8.1 Forecast 284
10.8.2 Key Events 287
10.8.3 Drivers and Barriers 288
10.9 China 289
10.9.1 Forecast 289
10.9.2 Key Events 292
10.9.3 Drivers and Barriers 292
11 Appendix 294
11.1 Bibliography 294
11.2 Abbreviations 321
11.3 Methodology 329
11.4 Forecasting Methodology 329
11.4.1 Diagnosed HER2-Negative Breast Cancer Patients 329
11.4.2 Percentage of Drug-Treated Patients 330
11.4.3 Drugs Included in Each Therapeutic Class 330
11.4.4 Launch and Patent Expiry Dates 331
11.4.5 General Pricing Assumptions 332
11.4.6 Individual Drug Assumptions 334
11.4.7 Generic Erosion 342
11.4.8 Pricing of Pipeline Agents 342
11.5 Primary Research – KOLs Interviewed for This Report 353
11.6 Primary Research – High-Prescriber Survey 355
11.7 About the Authors 356
11.7.1 Analyst 356
11.7.2 Director of Oncology 356
11.7.3 Epidemiologist 357
11.7.4 Director of Epidemiology 357
11.7.5 Global Head of Healthcare 358
11.8 About GlobalData 359
11.9 Disclaimer 359
【レポート販売概要】
■ タイトル:HER2陰性乳癌治療薬の世界市場予測および分析■ 英文:PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023
■ 発行日:2015年1月31日
■ 調査会社:GlobalData
■ 商品コード:GDHC92PIDR
■ 調査対象地域:グローバル
- 自己免疫疾患用薬の世界市場2016-2020About Autoimmune Diseases Drugs Autoimmune diseases are immunological disorders that occur when the immune system attacks and destroys healthy tissues in the body rather than foreign bodies, causing significant pain, inflammation, and organ damage. These diseases can affect the nervous system, cardiovascular system, and musculoskeletal system or individual organs, including the skin, lungs, kidney …
- 細胞及び組織分析製品の世界市場:細胞・組織キャラクタリゼーション、生体試料作製、細胞・組織分離About Cell and Tissue Analysis Products Cell and tissue analysis refers to the study of cells or tissues to identify and analyze the structure and function of cells and tissues. Various biospecimen preparation, cell and tissue separation, and cell and tissue characterization products are used to isolate and assess cells and tissue. The predominant technologies used in cell and tissue analysis are …
- 呼吸器疾患の検査/診断の世界市場分析:製品別(画像検査、呼吸計、血液ガス試験)、エンドユーザー別(病院、医師クリニック、臨床検査室、外来サービス)、セグメント予測、2014-2025The global respiratory diseases testing market is expected to reach USD 6.7 billion by 2025, according to a new report by Grand View Research, Inc. The market is driven by the rising prevalence of respiratory diseases. As per Forum of International Respiratory Societies, more than 200 million people across the globe suffered from Chronic Obstructive Pulmonary Disease (COPD) and 235 million suffere …
- 鉛(Lead)の世界市場動向2014/2015The report presents a thorough study of lead, covering both global and regional markets. It aims to give a proper picture of the market, its trends, perspectives and opportunities. Comprehensive data showing lead worldwide production, consumption, trade statistics and prices are provided. Each country’s market overview covers the following: lead production in the country, major manufacturers, lead …
- インターベンショナル心臓装置および末梢血管用装置の世界市場予測(~2021):血管形成術用バルーン、ステント、カテーテル、EVARステントグラフト、腹大動脈瘤、IVCフィルターThe global interventional cardiology and peripheral vascular devices market is segmented into angioplasty balloons, angioplasty stents, catheters, EVAR stent grafts, IVC filters, plaque modification devices, hemodynamic flow alteration devices, and accessories. Factors such as the aging population, rising incidence of cardiovascular diseases, increasing demand of minimally invasive procedures, and …
- 自動車産業における産業用ロボットの世界市場:多関節ロボット、直角座標ロボット、SCARAロボット、円筒座標ロボットAbout Industrial Robotics Industrial robotics can be defined as the use of robots in the manufacturing processes of industries such as food and beverage, electronics, and automotive. Industrial robots are programmed to control and automate manufacturing processes in industries. They are classified according to various technical parameters such as number of axes, degrees of freedom, working envelop …
- 世界主要国における結核検査市場2015The report presents a detailed analysis of the Tuberculosis diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Tuberculosis definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals   …
- Fatigue:グローバル臨床試験レビューH1, 2013Fatigue Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Fatigue Global Clinical Trials Review, H1, 2013" provides data on the Fatigue clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fatigue. It includes an overview of the trial numbers and their recruitment status as per the site of trial conductio …
- アジアの呼吸装置市場Asia-Pacific Respiratory Devices Market Outlook to 2021 Summary GlobalData’s new report, "Asia-Pacific Respiratory Devices Market Outlook to 2021", provides key market data on the Asia-Pacific Respiratory Devices market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segments - Humidifiers, Oxygen Concentrators, Ventila …
- 世界のスマートフォン用パワー・マネージメントIC市場(2014-2018)About Smartphone Power Management Integrated Circuit Power management integrated circuits are used to manage power requirements and support voltage scaling and power delivery sequencing in power electronic devices. They are the key components in any electronic device with a power supply, battery, or power cord, and optimize power usage. They are used in electronic systems such as cellphones, TVs, …
- 心臓超音波検査(ECG)装置の世界市場2017-2021ABSTRACTAbout Echocardiography Devices ECG is a process of recording the electrical signals associated with cardiac activity over a period of time. It has become a routine part of any medical evaluation and has been used as a diagnostic test in the past seven decades. ECG is used for the diagnosis and treatment of various types of heart conditions such as myocardial infarctions (heart attacks) and …
- 世界のマイクロ波装置市場予測及び分析(2014 – 2019):クライストロン、サイラトロン、進行波管などThe report provides an in-depth analysis of the global microwave devices market. It gives information about the various types of microwave tubes such as Klystron, Magnetron, TWT, and Thyratron with respect to geography, application, type, and the current market scenario. The global microwave devices market is expected to grow at a CAGR of 3.40% and reach $1.2 billion by 2019. The global microwave …
- 主変圧器の世界市場:タップ付変圧器、タップ切換変圧器、整流器変圧器About Traction Transformer A traction transformer is a major equipment in the electric traction system of trains, which is powered by electricity. It forms the most integral part of the electric traction system and helps in the smooth movement of motors such as locomotives, high-speed trains, and trams. Traction transformer is used to bring down the voltage from the overhead electric line, i.e., 1 …
- ワクチンの世界市場販売分析:小児用ワクチン、成人用ワクチン、高齢者用ワクチン、トラベルワクチン、治療ワクチンVaccines – Your 2016 Guide to Developments, Opportunities and RevenuesWhat does the future hold for vaccine sales? Visiongain’s updated report shows you forecasted sales at overall world market, submarket, product and national level to 2026. With that study you discover vaccine trends, R&D and revenue prospects for human healthcare. That way you can benefit your research, analysis, decisions and a …
- 世界のRNAi薬パイプライン分析“Global RNAi Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed based upon RNAi technology. Research report covers all the ongoing drugs being developed in various development phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Me …